地缘冲突再次升级，波动市中的财富机会分享，你不会想错过的
Master Options Trading with 5mins Comic
we’ve condensed the complex world of options into 20 easy-to-read comics. In just 5 minutes, we'll transform your mindset, break down the safest beginner strategies, and show you exactly what to watch out for before placing your very first order.

$ImmunityBio (IBRX.US)$ Let's witness together. How much momentum can cancer drugs unleash.

$ImmunityBio (IBRX.US)$
Sure enough, anything can happen in a dream.
It's wonderful to have you in my dreams.
How great it would be if you were also in reality.

$ImmunityBio (IBRX.US)$ Could there be a sudden surge if the trend reverses

$CONTRA: DATAVAULT AI INCOMMON STOCK (DVLT.CNT.US)$
No idea what this is about

Most medical research institutes fail to achieve results and end up going bankrupt, burdened with significant debt.
Once a successful development occurs, it will inevitably lead to a sharp increase, potentially even raising the company's valuation.
$ImmunityBio (IBRX.US)$ It seems that the main pre-market trading reached 11.2. So today, it could go above 15https://www.youtube.com/live/DKd8YPX3gWc?si=9GLKChbj06ZSeD4C

$ImmunityBio (IBRX.US)$ beware any huge gap up in premarket. My experience is it always comes down when market opens

$Figma Inc (FIG.US)$Although I don't have any positions, I still want to encourage those who are holding! It's been six weeks since we started shorting the put options at the issuance price with the aim of exercising and acquiring shares. However, despite earning nearly 100,000 in premiums, we still haven't managed to acquire actual shares, indicating that sellers at the issuance price simply aren't willing to part with them. Shorts currently dare not make any rash moves, as last quarter's one-time stock-based compensation provision of 1 billion (a reasonable reward, reflecting years of hard work by executives planned before the IPO) ensures that this quarter's earnings per share will undoubtedly soar. Based on my cash flow model projections, EPS is expected to rise from -2.74 to -0.25, and reach approximately +0.35 in the next quarter! Under these circumstances, who would dare to short? The current valuation at 16 times price-to-sales isn’t much higher than Adobe’s, yet its fundamentals are far superior! Its product competitiveness far exceeds Adobe's. Every morning when you wake up, Adobe loses 23-28 paying customers to FIG. As for some shortsighted executives selling shares, there is no need to worry. Their reductions are partly due to tax reasons, and partly driven by a desire to cash out after sudden wealth. Remember Tesla in the summer of 2014? The stock price surged sevenfold in just over a year, prompting a wave of insider selling, including Musk's brother, around the 200 mark. At that time, everyone said Tesla was finished! Look at it today—Tesla's stock price is now at 7,300 (adjusted). As the design software stock most closely integrated with AI, FIG not only continues to grow but also holds 1.6 billion in cash. It cannot possibly fall much further...

$ImmunityBio (IBRX.US)$ So many studies and waiting for approval.
#Believe that it won't be long before we see the share price rise to $80 per share
#If acquired by a major pharmaceutical leader, each share could reach $300